Skip to main content

Table 4 Bi-variable and multi-variable logistic regression analysis of factors associated with PIVC phlebitis among admitted patients at University of Gondar hospital, Northwest Ethiopia, April 1, 2020 to August 31, 2020

From: Incidence of peripheral intravenous catheter phlebitis and its associated factors among patients admitted to University of Gondar hospital, Northwest Ethiopia: a prospective, observational study

Variables

Phlebitis

COR (CI)

P-value

AOR (CI)

P-value

Yes

No

Age (years)

 18–40

42

127

1

 

1

 

 40–60

43

82

1.59 (0.91–2.77)

0.104

1.19 (0.55–2.58)

0.650

 > 60

31

59

1.02 (0.57–1.77)

0.995

0.89 (0.45–1.75)

0.730

Gender

 Male

128

71

1

 

1

 

 Female

140

454

0.58 (0.37–0.90)

0.016

0.29 (0.13–0.63)

0.002

Residence

 Urban

119

60

1

 

1

 

 Rural

149

56

0.75 (0.48–1.15)

0.187

0.65 (0.33–1.28)

0.209

Religion

 Christian

246

97

1

 

1

 

 Muslim

23

18

2.07 (1.06–4.02)

0.033

1.86 (0.71–4.91)

0.210

Educational level

 Unable to read and write

126

41

1

 

1

 

 Able to read and write

28

23

1.09 (0.54–2.20)

0.817

1.53 (0.47–5.02)

0.483

 Elementary school

44

23

0.47 (0.21–1.08)

0.077

0.77 (0.23–2.62)

0.680

 Secondary school

37

12

0.74 (0.34–1.65)

0.467

1.04 (0.33–3.31)

0.942

 College and above

36

14

1.19 (0.49–2.94)

0.692

1.86 (0.59–5.75)

0.284

Admission diagnosis

 Lung disease

69

28

1

   

 Heart disease

42

26

0.90 (0.47–1.72)

0.749

1.3 (0.6–2.81)

0.511

 CNS disease

47

18

0.59 (0.3–1.17)

0.130

0.75 (0.33–1.70)

0.488

 Liver disease

17

4

0.95 (0.46–1.97)

0.897

1.32 (0.56–3.09)

0.522

 Renal disease

8

8

1.55 (0.47–5.10)

0.469

1.74 (0.48–6.34)

0.404

 Hematological diseases

12

6

1.22 (0.31–4.82)

0.78

1.19 (0.26–5.46)

0.826

 Fracture

10

3

0.37 (0.12–1.09)

0.07

0.45 (0.12–1.64)

0.225

 Others

63

23

0.57 (0.25–2.17)

0.572

1.3 (0.37–4.59)

0.688

Co-morbidities

 Diabetes

  Yes

26

12

1.07 (0.52–2.21)

0.85

  

  No

242

104

1

   

 Hypertension

  Yes

57

32

0.71 (0.43–1.17)

0.179

1.08 (0.57–2.05)

0.804

  No

211

84

1

 

1

 

 HIV/AIDS

  Yes

12

12

1

 

1

 

  No

115

44

0.43 (0.18–1.00)

0.050

0.56 (0.20–1.58)

0.275

  Unknown

141

60

1.11 (0.70–1.76)

0.651

1.22 (0.71–2.11)

0.488

 CKD

  Yes

20

10

1.17 (0.53–2.58)

0.69

  

  No

250

104

1

   

 Malignancy

  Yes

22

8

1.07 (0.50–2.54)

0.64

  

  No

248

106

1

   

 Concomitant bacterial infections

 Yes

168

75

1.09 (0.69–1.72)

0.71

  

  No

100

41

1

   

Duration of hospital stay

 < 3 days

19

7

1

 

1

 

 3–7 days

89

31

1.47 (0.55–3.93)

0.447

1.75 (0.56–5.48)

0.338

 7–14 days

110

51

1.55 (0.83–2.89)

0.167

1.73 (0.85–3.53)

0.131

 > 14 days

50

27

1.17 (0.66–2.07)

0.603

1.21 (0.63–2.32)

0.563

Place of procedure

 Emergency unit

146

57

1

   

 Wards

122

59

0.60 (0.07–5.70)

0.65

  

Catheter dwell time

 < 3 days

119

52

1

 

1

 

 3–4 days

66

17

1.3 (0.8–2.10)

0.294

1.21 (0.68–2.15)

0.511

 > 4 days

83

47

2.2 (1.16–4.18)

0.016

2.26 (1.09–4.70)

0.029

Cannula insertion site

 Dorsum of hand

95

53

0.85 (0.61–1.24)

0.422

  

 Forearm

144

57

0.91 (0.55–2.20)

0.652

  

 Antecubital fossa

29

6

1

   

Cannula size (gauge)

 18

4120

1

    

 20

218

93

1.00 (0.63–1.98)

1.000

  

 22

6

2

0.78 (0.16–3.94)

0.761

  

 24

3

1

0.68 (0.13–3.69)

0.660

  

Intravenous drugs use

 Yes

202

80

0.73 (0.45–1.18)

0.193

0.88 (0.49–1.59)

0.682

 No

66

36

1

 

1

 

Intravenous infusates use

 Yes

189

62

0.48 (0.31–0.75)

0.001

0.47 (0.28–0.79)

0.005

 No

79

54

1

 

1

 

Blood products use

 Yes

37

15

0.93 (0.49–1.77)

0.82

  

 No

231

101

1

   
  1. NB AIDS, acquired immune deficiency syndrome, AOR adjusted odds ratio, COR crude odds ratio, CI confidence interval, CKD chronic kidney disease, HIV human immune deficiency virus, PIVC peripheral intravenous catheter